Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

In this study, we enhanced the data analysis capabilities of the DARTS experiment by monitoring the changes in protein stability and estimating the affinity of protein-ligand interactions. The interactions can be plotted into two curves: a proteolytic curve and a dose-dependence curve. We have used mTOR-rapamycin interaction as an exemplary case.

Abstract

Drug Affinity Responsive Target Stability (DARTS) is a robust method for detection of novel small molecule protein targets. It can be used to verify known small molecule-protein interactions and to find potential protein targets for natural products. Compared with other methods, DARTS uses native, unmodified, small molecules and is simple and easy to operate. In this study, we further enhanced the data analysis capabilities of the DARTS experiment by monitoring the changes in protein stability and estimating the affinity of protein-ligand interactions. The protein-ligand interactions can be plotted into two curves: a proteolytic curve and a dose-dependence curve. We have used the mTOR-rapamycin interaction as an exemplary case for establishment of our protocol. From the proteolytic curve we saw that the proteolysis of mTOR by pronase was inhibited by the presence of rapamycin. The dose-dependency curve allowed us to estimate the binding affinity of rapamycin and mTOR. This method is likely to be a powerful and simple method for accurately identifying novel target proteins and for the optimization of drug target engagement.

Introduction

Identifying small molecule target proteins is essential to the mechanistic understanding and development of potential therapeutic drugs1,2,3. Affinity chromatography, as a classical method for identifying the target proteins of small molecules, has yielded good results4,5. However, this method has limitations, in that chemical modification of small molecules often results in reduced or altered binding specificity or affinity. To overcome these limitations, several new strategies have recently been developed and applie....

Protocol

1. Collect and lyse cells

  1. Grow 293T cells using Dulbecco's modified Eagle medium (DMEM) with 10% fetal bovine serum, 2 mM glutamine and 1% antibiotics. Incubate cultures at 37 °C under 5% CO2.
    NOTE: The growth state of the cells may affect the stability of subsequent experiments.
  2. Expand cells in culture until reaching 80‒90% confluence.
  3. Mix 345 μL of cell lysis reagent (see the Table of Materials) with 25 μL of 20x protease inhibi.......

Representative Results

The flow chart of the experiment is outlined in Figure 1. The result of Coomassie blue staining is shown in Figure 2. Incubation with the small molecule confers protection against proteolysis. Three bands that appear to be protected by incubation with rapamycin over vehicle control are found. The expected results from proteolytic curve experiment are shown in Figure 3. As a proof-of-principle, we examined the well-studied protein mT.......

Discussion

DARTS allows for identification of small molecule targets by exploiting the protective effect of protein binding against degradation. DARTS does not require any chemical modification or immobilization of the small molecule26. This allows small molecules to be used to determine their direct binding protein targets. Standard assessment criteria for the classical DARTS method include gel staining, mass spectrometry and western blotting12,13. .......

Acknowledgements

This work was supported partly by NIH research grants R01NS103931, R01AR062207, R01AR061484, and a DOD research grant W81XWH-16-1-0482.

....

Materials

NameCompanyCatalog NumberComments
100X Protease inhibitor cocktailSigma-AldrichP8340Dilute to 20X with ultrapure water
293T cell lineATCCCRL-3216DMEM medium with 10% FBS
Acetic acidSigma-AldrichA6283
BCA Protein Assay KitThermo Fisher23225
Calcium chlorideSigma-AldrichC1016
Cell scraperThermo Fisher179693
Coomassie Brilliant Blue R-250 Staining SolutionBio-Rad1610436
Dimethyl sulfoxide(DMSO)Sigma-AldrichD2650
GraphPad PrismGraphPad SoftwareVersion 6.0statistical analysis and drawing software
Hydrochloric acidSigma-AldrichH1758
ImageJNational Institutes of HealthVersion 1.52image processing and analysis software
M-PER Cell Lysis ReagentThermo Fisher78501
Phosphate-buffered saline (PBS)CorningR21-040-CV
PronaseRochePRON-RO10 mg/ml
Sodium chlorideSigma-AldrichS7653
Sodium fluorideSigma-AldrichS7920
Sodium orthovanadateSigma-Aldrich450243
Sodium pyrophosphateSigma-Aldrich221368
Trizma baseSigma-AldrichT1503adjust to pH 8.0
β-glycerophosphateSigma-AldrichG9422

References

  1. Rask-Andersen, M., Masuram, S., Schioth, H. B. The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annual Review of Pharmacology and Toxicology. 54, 9-26 (2014).
  2. O'Connor, C. J., Laraia, L., Spring, D. R.

Explore More Articles

DARTSDrug Affinity Responsive Target StabilityMTORRapamycinProtein ligand InteractionProteolytic CurveDose dependence Curve293T CellsCell LysisBCA AssayPronaseProtease Inhibitor CocktailSDS PAGE

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved